Zynex Announces Steven Dyson as New CEO
Zynex (NASDAQ: ZYXI), a medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring, has announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025.
Dyson brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. His extensive background includes significant board and transaction experience with various healthcare and medtech companies worldwide, including KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm.
Thomas Sandgaard, Zynex's Founder and current Chairman, will step back from day-to-day operations but remain actively involved as Chairman and Chair of the Board's Technology Committee. Dyson will operate from the company's headquarters in Englewood, Colorado, while maintaining a residence in London, England.
Zynex (NASDAQ: ZYXI), un'azienda di tecnologia medica specializzata in dispositivi medici non invasivi per la gestione del dolore, la riabilitazione e il monitoraggio dei pazienti, ha annunciato la nomina di Steven Dyson come nuovo Amministratore Delegato, con effetto dal 18 agosto 2025.
Dyson porta con sé oltre 25 anni di esperienza nel settore della tecnologia medica, principalmente grazie alla sua leadership presso Apax, una società globale di private equity. Il suo ampio background comprende una significativa esperienza in consigli di amministrazione e operazioni con diverse aziende nel campo sanitario e medtech a livello mondiale, tra cui KCI, Rodenstock, Healthium Medtech, Unilabs e Neuraxpharm.
Thomas Sandgaard, fondatore di Zynex e attuale Presidente, si ritirerà dalle operazioni quotidiane ma resterà attivamente coinvolto come Presidente e Presidente del Comitato Tecnologico del Consiglio di Amministrazione. Dyson opererà dalla sede dell'azienda a Englewood, Colorado, mantenendo però una residenza a Londra, Inghilterra.
Zynex (NASDAQ: ZYXI), una compañía de tecnología médica enfocada en dispositivos médicos no invasivos para el manejo del dolor, rehabilitación y monitoreo de pacientes, ha anunciado el nombramiento de Steven Dyson como su nuevo Director Ejecutivo, con efecto a partir del 18 de agosto de 2025.
Dyson aporta más de 25 años de experiencia en el sector de tecnología médica, principalmente a través de su liderazgo en Apax, una firma global de capital privado. Su amplia trayectoria incluye una importante experiencia en juntas directivas y transacciones con diversas empresas de salud y tecnología médica en todo el mundo, incluyendo KCI, Rodenstock, Healthium Medtech, Unilabs y Neuraxpharm.
Thomas Sandgaard, fundador de Zynex y actual presidente, se retirará de las operaciones diarias pero permanecerá activamente involucrado como Presidente y presidente del Comité de Tecnología del Consejo. Dyson trabajará desde la sede de la compañía en Englewood, Colorado, mientras mantiene una residencia en Londres, Inglaterra.
Zynex (NASDAQ: ZYXI)는 통증 관리, 재활 및 환자 모니터링을 위한 비침습 의료기기에 중점을 둔 의료기술 회사로, Steven Dyson을 신임 최고경영자(CEO)로 임명했다고 2025년 8월 18일부터 발효된다고 발표했습니다.
Dyson은 주로 글로벌 사모펀드 회사인 Apax에서의 리더십을 통해 의료기술 분야에서 25년 이상의 경력을 보유하고 있습니다. 그의 폭넓은 경력에는 KCI, Rodenstock, Healthium Medtech, Unilabs, Neuraxpharm 등 전 세계 다양한 헬스케어 및 메드테크 기업에서의 이사회 및 거래 경험이 포함되어 있습니다.
Zynex의 창립자이자 현재 회장인 Thomas Sandgaard는 일상 운영에서 물러나지만 회장 및 이사회 기술 위원회 의장으로서 적극적으로 참여할 예정입니다. Dyson은 콜로라도주 잉글우드에 위치한 회사 본사에서 근무하며 영국 런던에도 거주지를 유지할 것입니다.
Zynex (NASDAQ : ZYXI), une entreprise de technologie médicale spécialisée dans les dispositifs médicaux non invasifs pour la gestion de la douleur, la rééducation et la surveillance des patients, a annoncé la nomination de Steven Dyson en tant que nouveau Directeur Général, effective à partir du 18 août 2025.
Dyson apporte plus de 25 ans d'expérience dans le secteur des technologies médicales, principalement grâce à son rôle de direction chez Apax, une société mondiale de capital-investissement. Son parcours étendu inclut une expérience significative dans des conseils d'administration et des transactions avec diverses entreprises de santé et de medtech à travers le monde, notamment KCI, Rodenstock, Healthium Medtech, Unilabs et Neuraxpharm.
Thomas Sandgaard, fondateur de Zynex et actuel président, se retirera des opérations quotidiennes mais restera activement impliqué en tant que Président du Conseil et président du Comité Technologie du Conseil d'Administration. Dyson exercera depuis le siège de l'entreprise à Englewood, Colorado, tout en conservant une résidence à Londres, en Angleterre.
Zynex (NASDAQ: ZYXI), ein Medizintechnikunternehmen, das sich auf nicht-invasive medizinische Geräte zur Schmerzbehandlung, Rehabilitation und Patientenüberwachung spezialisiert hat, hat die Ernennung von Steven Dyson zum neuen Chief Executive Officer bekannt gegeben, wirksam ab dem 18. August 2025.
Dyson bringt über 25 Jahre Erfahrung im Bereich Medizintechnik mit, hauptsächlich durch seine Führungsrolle bei Apax, einer globalen Private-Equity-Gesellschaft. Sein umfangreicher Hintergrund umfasst bedeutende Erfahrungen in Vorständen und Transaktionen mit verschiedenen Gesundheits- und Medizintechnikunternehmen weltweit, darunter KCI, Rodenstock, Healthium Medtech, Unilabs und Neuraxpharm.
Thomas Sandgaard, Gründer von Zynex und derzeitiger Vorsitzender, wird sich aus dem Tagesgeschäft zurückziehen, aber weiterhin aktiv als Vorsitzender und Vorsitzender des Technologieausschusses des Vorstands engagieren. Dyson wird von der Firmenzentrale in Englewood, Colorado, aus arbeiten und gleichzeitig einen Wohnsitz in London, England, beibehalten.
- New CEO brings 25+ years of medical technology sector experience
- Extensive track record in acquiring, growing, and exiting healthcare companies
- Founder remains involved as Chairman and Technology Committee Chair, ensuring continuity
- New leadership focused on optimizing payer mix and returning to growth trajectory
- CEO will maintain dual residence between Colorado and London, potentially impacting operational efficiency
- Significant leadership transition may cause temporary organizational adjustments
Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee.
Steven brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. He has played a key role in acquiring, growing, and exiting numerous healthcare and medtech companies around the world. His board and transaction experience includes companies such as KCI (
Steven will operate from the Zynex headquarters in Englewood,
"I am excited to step back from day-to-day operations and continue contributing as Chairman," said Thomas Sandgaard. "Steven brings deep expertise and a proven track record in the medical sector. His leadership will be instrumental as we refocus our business strategy toward a more optimized payer mix and work to return Zynex to a strong growth trajectory."
Newly appointed CEO Steven Dyson added, "I'm honored to join the Zynex team at this exciting time in the Company's history and to have the opportunity to lead the Company back to a strong growth trajectory. Zynex's strong foundation, built by Thomas over many years, provides an excellent platform to deliver exceptional value for all our stakeholders "
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.
Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy; market conditions; the timing, scope and possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.
These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Dan Moorhead, CFO
ir@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-steven-dyson-as-new-ceo-302494092.html
SOURCE Zynex, Inc.
FAQ
Who is the new CEO of Zynex (NASDAQ: ZYXI)?
What is Steven Dyson's background before joining Zynex?
What will happen to Zynex's founder Thomas Sandgaard?
What are the main objectives for Zynex's new CEO?
Where will Zynex's new CEO be based?
